• For the diagnosis and treatment cervical dysplasia, which are accompanied by keratosis

For the diagnosis and treatment cervical dysplasia, which are accompanied by keratosis

HEALTH OF WOMAN. 2016.6(112):110–117 
 

For the diagnosis and treatment cervical dysplasia, which are accompanied by keratosis 
 

Lygyrda N. F., Krotevich M. S., Svintsitskyi V. S., Skoroda L. V.

The National Cancer Institute, Kyiv 
 

The study involved 76 patients with dysplasia of cervical epithelium mild to moderate manifestations of keratosis. At causal neoadjuvant therapy of patients divided into two groups: group A (38 patients) – 20 patients with moderate and 18 patients with mild dysplasia of cervical epithelium with the manifestations of keratosis. Group B (38 patients) – 20 patients with moderate and 18 patients with mild dysplasia of cervical epithelium with the symptoms of keratosis. A research group in the patient receiving therapy Allokin-alpha 1 mg subcutaneously № 6 in combination with a2b-interferon in the form of suppositories, 500 000 IU twice a day 14 days. In group B, patients received therapy a2b-interferon in the form of suppositories, 500 000 IU twice daily for 14 days. In the future, patients performed excision of the cervical transformation zone. Evaluation of colposcopic pattern in three weeks after the course showed that significantly more positive trend colposcopic pattern manifested in a decrease in the area and the degree of expression occurs in group A patients (86.8%) compared to 63.2% of patients in group B. The normal colposcopic feature after treatment determined in 97.4% of patients of group A, while in 31.6% of patients in the group are registered colposcopic residual sing keratosis.


Key words: cervix, keratosis, leukoplakia.


REFERENCES

1. Bauer G. 2008. Tsvetnoy atlas po kolposkopii. M, GEOTAR-Media:300.

2. Vorobiova LI, Lyhyrda NF. 2010. Porivniannia terapevtychnoi efektyvnosti zastosuvannia riznykh likarskykh form preparatu alfa-2-interferonu u khvorykh na TsIN I ta TsIN II. Zdorove zhenshchynы 5(51):42–46.

3. Gorpinchenko II, Gurzhenko YuN, Spiridonenko VV. 2015. Ratsionalnaya terapiya retsidivov papillomavirusnyih porazheniy polovyih organov u muzhchin. Zdorove muzhchinyi 1(52):114–118.

4. Duda AK, Kotsyubaylo LP, Okruzhnov NV. 2014. Primenenie protivovirusnogo preparata novogo pokoleniya Allokina-alfa v terapii sotsialno znachimyih virusnyih infektsiy. Aktualna InfektologIya 4(5):16–19.

5. Kovchur PI, Oleynik EK, Bahlaev IE, Churov AV. 2009. Vliyanie «Allokina-alfa» na ekspressiyu markerov regulyatornyih limfotsitov Treg u bolnyih s hronicheskoy papillomavirusnoy infektsiey. Izvestiya Samarskogo nauchnogo tsentra Rossiyskoy akademii nauk 11;1(5):958–961.

6. Kondrikov NI. 2008. Patologiya matki. M, Prakticheskaya meditsina:334.

7. Lyhyrda NF, Vorobeva LY, Krotevych MS. 2011. Osoblyvosti kolposkopichnoi diahnostyky peredraku ta pochatkovykh form raku shyiky matky. Klynycheskaia onkolohyia 1(1):56–60.

8. Ligirda NF, Vorobyova LI. 2002. Kliniko-laboratornoe obosnovanie kompleksnogo lecheniya tservikalnyih intraepitelialnyih neoplaziy. Zdorove zhenschinyi 4(12):23–27.

9. Наказ МОЗ України № 236 від 02.04.2014 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при дисплазії та раку шийки матки».

10. Патент (UA) Воробйова Л.І., Лигирда Н.Ф., Воронцова А.Л., Вінницька А.Б. Спосіб лікування передпухлинної патології шийки матки, обумовленої вірусом папіломи людини/ (Україна); Інститут онкології АМН України. – № 52344 А. Україна. 6МПК А 61 К 38/21; Заявл.11.04.2002. Бюл. № 12.

11. Podolskyi VV, Chernyshov VP, Zadorozhna TD. 2011. Skryninhovyi alhorytm diahnostyky ta likuvannia papilomavirusnoi infektsii shyiky matky u zhinok z porushenniamy reproduktyvnoho zdorov`ia. Metod. rekomendatsii. K:30.

12. Rogovskaya SI. 2013. Prakticheskaya kolposkopiya. 3-e izd., ispr. i dopol. M, GEOTAR-Media:240.

13. Bosch EX, Lorincz A, Munoz N et al. 2002. The causal relation between human papillomavirus and cervical cancer. J. din. Pathol. 55:244–265. http://dx.doi.org/10.1136/jcp.55.4.244

14. Dhanawada KR, Garrett L, Smith P et al. 1993. Characterizations of human keratinocytes transformed by high risk human papillomavirus types 16 or 18 and herpes simplex virus type 2. J. Gen. Virol. 74:955–963. http://dx.doi.org/10.1099/0022-1317-74-6-955; PMid:8389810

15. Harmsel B, Smedts F et al. 1999. Relationship between papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet. Gynecol. 93:46–50. http://dx.doi.org/10.1097/00006250-199901000-00011http://dx.doi.org/10.1016/S0029-7844(98)00306-8

16. Lane S, Wells M. 1994. Human papillomavirus, p53 and cervical neoplasia. J. Pathol. 172;4:299–300. http://dx.doi.org/10.1002/path.1711720402; PMid:8207608

17. Singer A, Monoghan JM. 2013. Lower Genital Tract Precancer. Colposcopy. 3rd ed. Elsivier.

18. Stubenrauch F, Laimins LA. 1999. Human papilomavirus life cycle: active and latent phases. Cancer biology. 9:379–386. http://dx.doi.org/10.1006/scbi.1999.0141; PMid:10712884

19. Weeler CE, Yamada T, Hildesheim A, Jenison SA. 1997. Human papillomavirus type 16 sequence variants: identification by E6 and LI lineage specific hybridization. J. Clin. Microbiol. 35;1:11-19.